title: Evidence-based management of bullous pemphigoid.
abstract: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease typically affecting the elderly. Although different therapeutic regimens have been proposed, a review of the evidence is needed to aid clinicians in their decision making and management. Systemic therapies such as corticosteroids and adjuvants are effective in BP but are plagued with adverse effects, and potent topical steroids are an alternative treatment. This article reviews the evidence supporting different therapeutic options in the management of BP.
authors.affiliation: Department of Dermatology, St George Hospital, Gray Street, Kogarah, Sydney, NSW 2217, Australia.
authors.forename: Benjamin S
authors.initials: BS
authors.lastname: Daniel
authors.forename: Luca
authors.initials: L
authors.lastname: Borradori
authors.forename: Russell P
authors.initials: RP
authors.lastname: Hall
authors.forename: Dédée F
authors.initials: DF
authors.lastname: Murrell
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009536:Niacinamide / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D001323:Autoantibodies; D003879:Dermatologic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D009536:Niacinamide; D001379:Azathioprine; D008727:Methotrexate